Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-06-06FDA Approved: LENVIMA — Supplemental Application (Eisai Inc.)
FDA approved a supplemental application for LENVIMA (lenvatinib) submitted by Eisai Inc.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
A post-marketing surveillance study of sorafenib (Nexavar) for renal cell carcinoma in Japan has completed.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Sorafenib (Nexavar) underwent post-marketing surveillance for renal cell carcinoma in Japan under an Early Access Program and the program ha…
-
CLINICAL_TRIALS research · 2018-05-14Clinical Trial Update: Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function [NA]
A clinical trial update exploring dynamic measurement of renal functional reserve to predict long-term kidney function, in adults with polyc…
-
CLINICAL_TRIALS trial_result · 2018-05-07Clinical Trial Update: A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers [Phase 2]
Phase 2 clinical trial evaluating tasquinimod in advanced/metastatic hepatocellular, ovarian, renal cell, and gastric cancers has been compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-05-04Clinical Trial Update: Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma [Phase 2]
Phase 2 trial of fosaprepitant for preventing chemotherapy-related nausea and vomiting in patients receiving high-dose interleukin-2 for met…
-
CLINICAL_TRIALS trial_result · 2018-05-03Clinical Trial Update: A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer [Phase 2]
Phase 2 study of famitinib in advanced/metastatic renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-30Clinical Trial Update: A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer [Phase 1]
A Phase 1 study evaluating varlilumab in combination with atezolizumab in patients with advanced cancers has been terminated.
-
CLINICAL_TRIALS trial_result · 2018-04-26Clinical Trial Update: Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib
Completed clinical trial validating the IMDC prognostic classification for second-line therapy in metastatic renal cell carcinoma after init…
-
CLINICAL_TRIALS trial_result · 2018-04-26Clinical Trial Update: Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques
A terminated clinical trial evaluating bone biomarkers for tyrosine kinase inhibitor response in renal cell carcinoma with bone metastases, …
-
CLINICAL_TRIALS trial_result · 2018-04-26Clinical Trial Update: Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
A retrospective study in metastatic renal cell carcinoma evaluating the efficacy and safety of targeted therapies after Pazopanib as first-l…
-
CLINICAL_TRIALS trial_result · 2018-04-19Clinical Trial Update: Safety Study of SGN-CD70A in Cancer Patients [Phase 1]
A Phase 1 safety study of SGN-CD70A in renal cell carcinoma and several lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma
The clinical trial update reports on plasma glycosaminoglycans as diagnostic and prognostic biomarkers in patients who have undergone surger…
-
FDA approval · 2018-04-12FDA Approved: EVEROLIMUS — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s Original Application for Everolimus, establishing a generic version of the branded drug. The a…
-
CLINICAL_TRIALS trial_result · 2018-04-04Clinical Trial Update: Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers [NA]
A completed pilot study evaluating neoadjuvant everolimus for advanced renal cell carcinoma, including biomarker analyses.
-
FDA approval · 2018-03-23FDA Approved: TORISEL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for TORISEL (temsirolimus) from Wyeth Pharmaceuticals (a Pfizer subsidiary).
-
CLINICAL_TRIALS research · 2018-03-13Clinical Trial Update: A Study of BCD-135 in Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for BCD-135 in patients with advanced solid tumors, including melanoma and non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study) [Phase 2]
Phase 2 clinical trial (Tokio Study) evaluating a third-line tyrosine kinase inhibitor after two prior TKIs in metastatic renal cell carcino…
-
CLINICAL_TRIALS withdrawal · 2018-03-05Clinical Trial Update: Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) [Phase 2]
Phase 2 trial of combining radiation with PD-1 inhibition in metastatic or recurrent renal cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer [Phase 2]
A Phase II trial of perifosine following tyrosine kinase inhibitor failure in renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2018-02-14Clinical Trial Update: A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation [NA]
A completed clinical trial comparing AirSeal integrated insufflation system with conventional insufflation for renal cell carcinoma; results…
-
CLINICAL_TRIALS trial_result · 2018-02-05Clinical Trial Update: Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) [Phase 4]
A Phase 4 clinical trial assessing outcome-related factors in patients with metastatic renal cell carcinoma treated with everolimus has been…
-
CLINICAL_TRIALS trial_result · 2017-12-29Clinical Trial Update: Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy [Phase 2]
Phase II study evaluating Anlotinib in patients with advanced renal cell carcinoma after TKI therapy failure or intolerance.
-
FDA approval · 2017-12-22FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS withdrawal · 2017-12-22Clinical Trial Update: REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT [Phase 3]
Phase 3 trial REDECT 2 for detecting clear cell renal cell carcinoma with PET/CT has been withdrawn.